NASDAQ:TNYA Tenaya Therapeutics (TNYA) Stock Price, News & Analysis $1.13 -0.03 (-2.59%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$1.16 +0.03 (+2.65%) As of 08/22/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Tenaya Therapeutics Stock (NASDAQ:TNYA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Tenaya Therapeutics alerts:Sign Up Key Stats Today's Range$1.12▼$1.2150-Day Range$0.56▼$1.2652-Week Range$0.36▼$4.01Volume2.33 million shsAverage Volume4.01 million shsMarket Capitalization$184.17 millionP/E RatioN/ADividend YieldN/APrice Target$6.25Consensus RatingBuy Company Overview Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California. Read More Tenaya Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks56th Percentile Overall ScoreTNYA MarketRank™: Tenaya Therapeutics scored higher than 56% of companies evaluated by MarketBeat, and ranked 462nd out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingTenaya Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageTenaya Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Tenaya Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Tenaya Therapeutics are expected to grow in the coming year, from ($1.35) to ($1.26) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tenaya Therapeutics is -1.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tenaya Therapeutics is -1.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTenaya Therapeutics has a P/B Ratio of 1.85. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Tenaya Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.89% of the float of Tenaya Therapeutics has been sold short.Short Interest Ratio / Days to CoverTenaya Therapeutics has a short interest ratio ("days to cover") of 4.3.Change versus previous monthShort interest in Tenaya Therapeutics has recently increased by 4.02%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTenaya Therapeutics does not currently pay a dividend.Dividend GrowthTenaya Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted7.89% of the float of Tenaya Therapeutics has been sold short.Short Interest Ratio / Days to CoverTenaya Therapeutics has a short interest ratio ("days to cover") of 4.3.Change versus previous monthShort interest in Tenaya Therapeutics has recently increased by 4.02%, indicating that investor sentiment is decreasing. News and Social Media2.1 / 5News Sentiment-0.28 News SentimentTenaya Therapeutics has a news sentiment score of -0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Tenaya Therapeutics this week, compared to 2 articles on an average week.Search Interest35 people have searched for TNYA on MarketBeat in the last 30 days. This is an increase of 119% compared to the previous 30 days.MarketBeat Follows11 people have added Tenaya Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 22% compared to the previous 30 days. Company Ownership4.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Tenaya Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $28,185.00 in company stock.Percentage Held by Insiders48.65% of the stock of Tenaya Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions90.54% of the stock of Tenaya Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Tenaya Therapeutics' insider trading history. Receive TNYA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tenaya Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address TNYA Stock News HeadlinesTenaya Therapeutics Reports Q2 2025 Financial ResultsAugust 14, 2025 | tipranks.comTenaya Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth ConferenceAugust 8, 2025 | globenewswire.comNations are at war over what’s in this boxA resource known as Element 29 is quickly becoming one of the most sought-after materials on the planet. Goldman Sachs calls it “The New Oil.” The International Energy Agency says it’s a cornerstone for electricity-related technologies. And the U.S. Department of Energy has officially classified it as “Critical.” Global demand is surging, supply is tightening fast, and one company may be positioned for a potential 3,500% windfall as the world races to secure it.August 24 at 2:00 AM | Behind the Markets (Ad)Tenaya Therapeutics reports Q2 EPS (14c), consensus (19c)August 7, 2025 | msn.comTenaya (TNYA) Q2 Loss Narrows 59%August 7, 2025 | fool.comTenaya Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 6, 2025 | globenewswire.comTenaya Therapeutics stock rises after positive safety reviews for heart gene therapiesJuly 30, 2025 | investing.comTenaya Receives Positive Safety Reviews from Independent DSMBs to Advance Both TN-201 and TN-401 Gene Therapy Clinical Trials as DesignedJuly 30, 2025 | globenewswire.comSee More Headlines TNYA Stock Analysis - Frequently Asked Questions How have TNYA shares performed this year? Tenaya Therapeutics' stock was trading at $1.43 on January 1st, 2025. Since then, TNYA shares have decreased by 21.0% and is now trading at $1.13. How were Tenaya Therapeutics' earnings last quarter? Tenaya Therapeutics, Inc. (NASDAQ:TNYA) issued its earnings results on Wednesday, August, 6th. The company reported ($0.14) earnings per share for the quarter, beating analysts' consensus estimates of ($0.20) by $0.06. When did Tenaya Therapeutics IPO? Tenaya Therapeutics (TNYA) raised $150 million in an initial public offering (IPO) on Friday, July 30th 2021. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. Who are Tenaya Therapeutics' major shareholders? Tenaya Therapeutics' top institutional investors include Geode Capital Management LLC (0.76%), Marex Group plc (0.25%), Jane Street Group LLC (0.23%) and Marshall Wace LLP (0.09%). Insiders that own company stock include Group Gp Lp Column III, David V Goeddel, Deepak Srivastava, Faraz Ali, Timothy Hoey, Whittemore Tingley, Tomohiro Higa and Chihiro Saito. View institutional ownership trends. How do I buy shares of Tenaya Therapeutics? Shares of TNYA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Tenaya Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Tenaya Therapeutics investors own include Voyager Therapeutics (VYGR), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), Waste Connections (WCN), American Water Works (AWK), DiamondRock Hospitality (DRH) and AU Optronics (AUOTY). Company Calendar Last Earnings8/06/2025Today8/24/2025Next Earnings (Estimated)11/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TNYA CIK1858848 Webwww.tenayatherapeutics.com Phone650-825-6990FaxN/AEmployees110Year FoundedN/APrice Target and Rating Average Price Target for Tenaya Therapeutics$6.25 High Price Target$9.00 Low Price Target$5.00 Potential Upside/Downside+453.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($0.96) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$111.13 million Net MarginsN/A Pretax MarginN/A Return on Equity-93.83% Return on Assets-75.66% Debt Debt-to-Equity RatioN/A Current Ratio6.00 Quick Ratio6.00 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.61 per share Price / Book1.85Miscellaneous Outstanding Shares162,980,000Free Float83,688,000Market Cap$184.17 million OptionableOptionable Beta3.01 Social Links 10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (NASDAQ:TNYA) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersNations are at war over what’s in this boxA resource known as Element 29 is quickly becoming one of the most sought-after materials on the planet. Goldm...Behind the Markets | SponsoredCould This Be the End of Retirement Worries?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTrump’s “new dollar” could shock Americans"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the big...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tenaya Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tenaya Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.